CB-0135 is under clinical development by Cosmo Pharmaceuticals and currently in Phase II for Limited/Distal Colitis. According to GlobalData, Phase II drugs for Limited/Distal Colitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CB-0135 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CB-0135 overview
Rifamycin (CB-01-35) is under development for the treatment of distal ulcerative colitis and proctitis. The drug candidate acts by targeting DNA directed RNA polymerase subunit beta and is administered by rectal route in the form of enema.
Cosmo Pharmaceuticals overview
Cosmo Pharmaceuticals (Cosmo) develops drugs for the treatment of gastrointestinal diseases and dermatology. It develops pharmaceutical products based on its multi-matrix technology. The company offers products such as Lialda, Mezavant, Mesavancol and Uceris for the treatment of ulcerative colitis. It also offers Eleview which is a submucosal injectable composition for use in gastrointestinal endoscopic procedures. The company’s manufacturing facility is located in Lainate, Milan. Cosmo is headquartered in Dublin, Ireland.
For a complete picture of CB-0135’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
